Literature DB >> 9157089

An association in non-insulin-dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism.

K Hawrami1, G A Hitman, M Rema, C Snehalatha, M Viswanathan, A Ramachandran, V Mohan.   

Abstract

In IDDM an association between diabetic retinopathy and polymorphic markers of MHC has been described. However, these associations are complicated by a primary association between the MHC and IDDM. Because the pathogenesis of retinopathy is likely to be the same in IDDM and NIDDM, NIDDM subjects with retinopathy would be the ideal population to study for an association with MHC markers. The following South Indian subjects were therefore studied: unselected NIDDM (n = 76), unselected IDDM (n = 99), non-diabetic controls (n = 96), NIDDM subjects with maculopathy (MAC), n = 55, NIDDM subjects with proliferative retinopathy (PR), n = 53, and without retinopathy (LTD), n = 46. DNA was amplified and studied using a microsatellite polymorphism located 3.5 kb upstream of TNF-beta within the MHC class III region on the short arm of chromosome 6. No differences in allelic distribution were observed between the random NIDDM subjects and controls (p = 0.17). Differences in allelic distribution were found between unselected IDDM and controls (P = 0.016) and between the NIDDM subjects with maculopathy and/or proliferative retinopathy and no retinopathy (P = 0.006). This association could be accounted for by those patients with proliferative retinopathy (MAC vs LTD, p = 0.23; MAC vs PR, p = 0.07; and PR vs LTD, p = 0.002).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9157089     DOI: 10.1016/0198-8859(95)00177-8

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

Review 1.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

Review 2.  Unraveling the role of genetics in the pathogenesis of diabetic retinopathy.

Authors:  Ashok Sharma; Maria L Valle; Connor Beveridge; Yutao Liu; Shruti Sharma
Journal:  Eye (Lond)       Date:  2019-01-24       Impact factor: 3.775

3.  Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy.

Authors:  G A Limb; L Webster; H Soomro; S Janikoun; J Shilling
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

4.  Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy.

Authors:  G A Limb; H Soomro; S Janikoun; R D Hollifield; J Shilling
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 5.  Anti-inflammatory therapy for diabetic retinopathy.

Authors:  Wenbo Zhang; Hua Liu; Modesto Rojas; Robert W Caldwell; Ruth B Caldwell
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

6.  Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy.

Authors:  J Salzmann; G A Limb; P T Khaw; Z J Gregor; L Webster; A H Chignell; D G Charteris
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

7.  Correlation of p21 gene codon 31 polymorphism and TNF-alpha gene polymorphism with nasopharyngeal carcinoma.

Authors:  Ming-Hsui Tsai; Wen-Chi Chen; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

8.  The role of concomitant immunosuppressants in impeding the progression of diabetic retinopathy: A pilot study.

Authors:  Premnath Raman; Rupal Kathare
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

Review 9.  Inflammation and pharmacological treatment in diabetic retinopathy.

Authors:  Snježana Kaštelan; Martina Tomić; Antonela Gverović Antunica; Jasminka Salopek Rabatić; Spomenka Ljubić
Journal:  Mediators Inflamm       Date:  2013-10-28       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.